Author:
Fronkova E,Mejstrikova E,Avigad S,Chik K W,Castillo L,Manor S,Reznickova L,Valova T,Zdrahalova K,Hrusak O,Jabali Y,Schrappe M,Conter V,Izraeli S,Li C K,Stark B,Stary J,Trka J
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference31 articles.
1. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer—Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339: 591–598.
2. Coustan Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96: 2691–2696.
3. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731–1738.
4. Arico M, Baruchel A, Bertrand Y, Biondi A, Conter V, Eden T et al. The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29–30, 2005. Leukemia 2005; 19: 1145–1152.
5. Pui CH, Relling MV, Sandlund JT, Downing JR, Campana D, Evans WE . Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol 2004; 83 (Suppl 1): S124–S126.
Cited by
62 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献